This outcome suggests that the loss of SMARCB1 may enhance the activation of compensatory cancer signaling pathways, allowing A549 lung cancer cells to evade the inhibitory effects of this anti-cancer compound “afatinib” (Fig. 3B). This evidence concerns the gene SMARCB1 and lung cancer.